Loxitane im, Adasuve(loxapine)
Adasuve, Loxitane (loxapine) is a small molecule pharmaceutical. Loxapine was first approved as Loxitane im on 1982-01-01. It is used to treat psychotic disorders and schizophrenia in the USA. It has been approved in Europe to treat bipolar disorder and schizophrenia. The pharmaceutical is active against 5-hydroxytryptamine receptor 2C, D(4) dopamine receptor, D(2) dopamine receptor, D(3) dopamine receptor, and 5-hydroxytryptamine receptor 2A. In addition, it is known to target 5-hydroxytryptamine receptor 6, histamine H1 receptor, potassium channel subfamily T member 1, and 5-hydroxytryptamine receptor 7.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
---|---|
mental disorders | D001523 |
Trade Name
FDA
EMA
Adasuve (generic drugs available since 1988-06-15, discontinued: Loxitane, Loxitane c, Loxitane im)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
psychotic disorders | — | D011618 | F20.81 |
schizophrenia | EFO_0000692 | D012559 | F20 |
Agency Specific
FDA
EMA
No data
HCPCS
Code | Description |
---|---|
J2062 | Loxapine for inhalation, 1 mg |
Clinical
Clinical Trials
27 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Psychomotor agitation | D011595 | — | — | 1 | 2 | 3 | 6 | ||
Healthy volunteers/patients | — | 2 | — | — | 2 | — | 4 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Schizophrenia | D012559 | EFO_0000692 | F20 | 1 | 1 | 1 | — | 1 | 4 |
Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | — | 2 | — | — | 2 |
Emergence delirium | D000071257 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Migraine disorders | D008881 | EFO_0003821 | G43 | — | 2 | — | — | — | 2 |
Neuralgia | D009437 | EFO_0009430 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Asthma | D001249 | EFO_0000270 | J45 | 1 | — | — | — | — | 1 |
Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | 1 | — | — | — | — | 1 |
Cigarette smoking | D000073865 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Respiratory insufficiency | D012131 | HP_0002093 | J96.9 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | LOXAPINE |
INN | loxapine |
Description | Loxapine is a dibenzooxazepine. It has a role as an antipsychotic agent and a dopaminergic antagonist. |
Classification | Small molecule |
Drug class | tricyclic compounds |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CN1CCN(C2=Nc3ccccc3Oc3ccc(Cl)cc32)CC1 |
Identifiers
PDB | — |
CAS-ID | 1977-10-2 |
RxCUI | 6475 |
ChEMBL ID | CHEMBL831 |
ChEBI ID | 50841 |
PubChem CID | 3964 |
DrugBank | DB00408 |
UNII ID | LER583670J (ChemIDplus, GSRS) |
Target
Agency Approved
HTR2C
HTR2C
DRD4
DRD4
DRD2
DRD2
DRD3
DRD3
HTR2A
HTR2A
Organism
Homo sapiens
Gene name
HTR2C
Gene synonyms
HTR1C
NCBI Gene ID
Protein name
5-hydroxytryptamine receptor 2C
Protein synonyms
5-HT-1C, 5-HT1C, 5-hydroxytryptamine (serotonin) receptor 2C, G protein-coupled, 5-hydroxytryptamine receptor 1C, serotonin 5-HT-1C receptor, serotonin 5-HT-2C receptor, Serotonin receptor 2C
Uniprot ID
Mouse ortholog
Htr2c (15560)
5-hydroxytryptamine receptor 2C (Q5WRU6)
Alternate
HTR6
HTR6
HRH1
HRH1
KCNT1
KCNT1
HTR7
HTR7
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,132 documents
View more details
Safety
Black-box Warning
Black-box warning for: Adasuve, Loxapine
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,647 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more